Sanofi: could acquire Mirati
(CercleFinance.com) - Sanofi is considering the acquisition of Mirati Therapeutics, according to Bloomberg.
This company develops anticancer products, in particular.
The company is based in Switzerland and the US. The stock jumped nearly 45% yesterday on Wall Street yesterday.
The company is developing several products in the clinic, including two Ph III studies and 5 Ph II studies, as monotherapy or in combination in various cancer indications, Invest Securities says.
At end-July, Sanofi signed a definitive agreement in the US to acquire Qunol, a leading American brand in the health and wellness market.
This transaction will strengthen the vitamins, minerals and supplements (VMS) range of Sanofi's Consumer Healthcare business.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This company develops anticancer products, in particular.
The company is based in Switzerland and the US. The stock jumped nearly 45% yesterday on Wall Street yesterday.
The company is developing several products in the clinic, including two Ph III studies and 5 Ph II studies, as monotherapy or in combination in various cancer indications, Invest Securities says.
At end-July, Sanofi signed a definitive agreement in the US to acquire Qunol, a leading American brand in the health and wellness market.
This transaction will strengthen the vitamins, minerals and supplements (VMS) range of Sanofi's Consumer Healthcare business.
Copyright (c) 2023 CercleFinance.com. All rights reserved.